Point72 Hong Kong LTD Neurocrine Biosciences Inc Call Options Transaction History
Point72 Hong Kong LTD
- $1.5 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding NBIX
# of Institutions
651Shares Held
97.1MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.92 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.34 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$748 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$657 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$361 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...